Disclosures for "Long-term Follow-up of m.11778G>A MT-ND4-LHON Patients Treated with Lenadogene Nolparvovec Ocular Gene Therapy: the RESTORE Study")
-
Dr. Biousse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gensights Biologic. Dr. Biousse has received personal compensation in the range of $0-$499 for serving as a Consultant for Neurophoenix. The institution of Dr. Biousse has received research support from NIH. Dr. Biousse has received publishing royalties from a publication relating to health care. Dr. Biousse has received publishing royalties from a publication relating to health care.
-
Dr. Newman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GenSight. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chiesi. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurophoenix. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke. Dr. Newman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurodiem. The institution of Dr. Newman has received research support from GenSight. The institution of Dr. Newman has received research support from Chiesi/Santhera. The institution of Dr. Newman has received research support from NINDS/NIH. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care.
-
Patrick Yu-Wai-Man has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GenSight Biologics.
-
Dr. Carelli has received personal compensation in the range of $0-$499 for serving as a Consultant for Chiesi Farmaceutici. Dr. Carelli has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Chiesi Farmaceutici.
-
Dr. Moster has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Gensight . Dr. Moster has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viridian. Dr. Moster has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi Genzyme.
-
Dr. Vignal-Clermont has nothing to disclose.
-
Dr. Klopstock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GenSight Biologics. Dr. Klopstock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chiesi GmbH. Dr. Klopstock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chiesi GmbH. Dr. Klopstock has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Chiesi GmbH. Dr. Klopstock has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for GenSight Biologics.
-
Dr. Sadun has received publishing royalties from a publication relating to health care.
-
Dr. Sergott has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Sergott has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Sergott has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen.
-
Magali Taiel has nothing to disclose.
-
Jose-Alain Sahel has received stock or an ownership interest from Prophesee. Jose-Alain Sahel has received stock or an ownership interest from Pixium Vision. Jose-Alain Sahel has received stock or an ownership interest from Tilak Healthcare. The institution of Jose-Alain Sahel has received research support from LabEx LIFESENSES (ANR-10-LABX-65). The institution of Jose-Alain Sahel has received research support from IHU FOReSIGHT (ANR-18-IAHU-01). The institution of Jose-Alain Sahel has received research support from ERC Synergy "HELMHOLTZ".